🔴 Where Nevada Stands Right Now (May 2026)

The Nevada State Board of Pharmacy held a formal public hearing on April 16, 2026 to consider placing kratom alkaloids (mitragynine and 7‑hydroxymitragynine) into Schedule I as part of LCB rulemaking file R038‑26. Kratom is NOT yet scheduled in Nevada. The proposal is still under review.

This is not over – far from it. The Board has not yet adopted the regulation. Public pressure right now matters more than ever.

🔄 Where It Is in the Pipeline

✅ This is rulemaking, not legislation. The Board must review and respond to submitted comments – they become part of the official justification record.

Why Technical Arguments Matter – Even When You’ve Lost Someone

If you have lost a child or loved one to kratom, your grief is valid and your pain is real. But the Nevada Board of Pharmacy is not a legislative body – it is a technical regulatory agency. Board members are pharmacists, not politicians. They are trained to respond to enforceability, chemistry, toxicology, and public health data – not emotional testimony.

This is not unfair – it is how administrative law works. If you want to stop kratom, you must speak the Board’s language. The most effective comment is cold, precise, and unassailable. Use the template below. It is designed to create a legal record that cannot be ignored.

Your grief can fuel your advocacy – but the weapon you hand the Board must be technical.

📋 Why Kratom Meets Every Schedule I Criterion

• High abuse potential: Mu‑opioid receptor agonism produces euphoria, tolerance, and compulsive redosing. Withdrawal syndrome documented in clinical literature – identical to classic opioids.
• No accepted medical use: FDA has repeatedly rejected kratom for any therapeutic indication. No FDA‑approved drug contains mitragynine. DEA has declined to reschedule.
• Lack of safety under medical supervision: Even in clinical settings, kratom causes seizures, liver toxicity, respiratory depression, and cardiac arrhythmias – no safe dose established.
• No reliable field test for law enforcement: Officers cannot distinguish legal “natural leaf” from concentrated extract or synthetic 7‑OH at point of sale – makes enforcement impossible.
• Documented contamination: Independent COAs show lead at 1 µg/g and ethanol at 15‑16% in popular brands – heavy metals, bacteria, and adulterants are routine.
• Variability kills: Alkaloid content varies 10‑fold between batches. Consumers cannot dose safely. Accidental overdose is inevitable.
• Emergence of synthetic derivatives: Unregulated labs now produce 7‑hydroxymitragynine at 50‑100x the potency of natural leaf – yet sold under same name. No regulatory distinction exists.
• No antidote: Unlike opioids, naloxone does not reliably reverse kratom overdose. Emergency rooms treat blindly.
• CDC SUDORS data: Hundreds of deaths with mitragynine detected – often with no other substances. Toxicologists increasingly point to kratom as primary cause.
• Pediatric exposure: Poison control centers receive hundreds of calls annually for children under 12 who accidentally ingested kratom – lead contamination poses lifelong neurodevelopmental risk.

Schedule I is not an overreach – it is the only classification that matches the drug’s pharmacology and the market’s reality.

📧 Submit Your Official Comment (Support Schedule I)

Send your comment to the Board’s official public comment inbox. It will be logged into the regulatory record before adoption.

✍️ Use this letter as a template

Click the button above to open your email client. Then copy the letter from the box above, paste it into the email body, add your name and city, and send.

📬 Who to Contact – Board of Pharmacy

This is rulemaking, not legislation. The Board of Pharmacy makes the decision. Legislators are not involved at this stage. Focus your pressure here:

⚡ The Window Closes After June 4

You are not late – you are sitting in the last meaningful intervention window.
Send your comment now. Support Schedule I for kratom.